Fire causes Sharpsburg VFW to close temporarily
Southern Allegheny Valley Emergency Services said bells began going off inside the building on the 1000 block of Main Street at 5:38 a.m. on Sunday.
After getting inside, firefighters saw flames coming from the bar.
The fire was quickly extinguished but the VFW said it will be closed until further notice.
No injuries were reported.
Download the FREE WPXI News app for breaking news alerts.
Follow Channel 11 News on Facebook and Twitter. | Watch WPXI NOW
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Strong First-Day Attendance at LAUSD Schools Despite Immigration Fears
This article was originally published in EdSource. Four days after a 15-year-old with a disability was mistakenly detained and handcuffed by immigration agents outside of Arleta High School, the first day of the new school year in the Los Angeles Unified School District seemed normal. Students at Arleta High walked through the school's annual red carpet on Thursday as music played and cheerleaders performed. Teachers, like Nicole Patin, greeted them while passing out flyers in English and Spanish to parents and red cards detailing what to do if stopped or detained by an ICE agent. Close friends and former colleagues joined in to welcome the students, including some of Patin's former students. Get stories like this delivered straight to your inbox. Sign up for The 74 Newsletter 'It was actually even emotional, because they just decided to show up,' said Patin, who also serves as chair of the school's United Teachers Los Angeles chapter. 'People that, at one point, were dear friends that had worked, people that were retired, they all came out to help us kick the year off in the right way.' Similar sentiments reigned across Los Angeles Unified as students returned to school, district officials said during a press conference at Gardena High School. And amid heightened immigration fears, district Superintendent Alberto Carvalho touted a 92% attendance rate districtwide — two percentage points higher than last year, a direct result of outreach that included more than 11,000 phone calls and 1,000 home visits. 'We're very proud of you, and I just want to echo our happiness and congratulations on all the things that you've done today, and we know that you're not going to stop, that this will be a continuation,' State Superintendent of Instruction Tony Thurmond said at the press conference. 'The state of California and our office will continue to support you in your work.' The district's Region South had the lowest rate of attendance, which Carvalho suspected was due to the area being home to more Immigration and Customs Enforcement (ICE) activity and parents' fears. He did not disclose the number. Related In response to current immigration activity, he said the district would ramp up its iAttend program — where school and district staff knock on the doors of families and encourage students to return to the classroom — from a quarterly to a monthly activity. He also said that following a 300-student increase, or 7% uptick, in virtual academy enrollment last week, about 200 families changed their minds and reenrolled their children in one of LAUSD's regular, in-person campuses 'as a result of increased trust and confidence specific to the protection protocols.' '[Today] was a great day of joy, of happiness, of community that was celebrated by students, parents and staff alike,' Carvalho said. 'The fear is real, that the anxiety is undeniable, that the concern in the minds and hearts of parents is strong. But many parents told us that the steps we took [involving several tiers of protection and safety zones surrounding schools] … created an environment where parents believed that the best place for their children would be the schoolhouse.' ICE activity took place on Tuesday, near several schools, but no closer than two blocks away. The schools were: Danny J. Bakewell Sr., Primary Center and Bret Harte Preparatory Middle School in Region South Mendez High School, Ramon C. Cortines School of Visual and Performing Arts and Castelar Elementary School in Region East Victory Boulevard Elementary and STEAM Magnet in Region North Everyone involved was quick to communicate and respond, and 'no impact was seen or felt by these schools as a result of these federal actions in the neighborhood,' Carvalho said. The superintendent also said the district is working actively with two impacted families. One is the family of an 18-year-old Reseda High School student who was detained while walking his dog and is currently in a detention center in Los Angeles. Carvalho said the boy's mother told him, 'My son is in a small space with 40 men, most of them, if not all of them, much older than he is. He is 18 years old, but he's a kid. He has not been exposed to anything in his life. He drinks water once a day. The food is insufficient.' The second involved a student who was taken to a detention center in Texas but has since been released. 'Armed men in hoods with masks jumping out of vehicles with militarized vests with long guns in hand. … It's shocking for most adults,' Carvalho said. 'Think for a second about the impact that this has on impressionable young children. … I'm a father. I would not want my child to witness that.' He and school board member Tanya Ortiz Franklin urged families to contact their school's principal if they need help with transportation. Carvalho said they have so far met the needs of more than 300 families who have requested special accommodation, including modifications of bus routes and potential door-to-door services. 'In some ZIP codes in our country, the children will never witness [detentions]. Never,' Carvalho said. 'And then there are kids in [other regions who] walk to school. Blocks. … Can we spare, beyond politics, policy and legalities, can we spare our children from that trauma?' Patin, the Arleta High School teacher, said attendance remained strong on her campus and in her classrooms. 'Our campus is very secure. Our office is locked. … There's no strangers or people just dropping in or having access to our campus,' she said. 'That's really never been that way. But we're especially vigilant now.' And while the overall energy was positive, she said the immigration raids have impacted students. Many, she said, had watched violent interactions on social media and feared for themselves or family members. 'When class started, they wanted to talk about all of the people that were out in front of school and the reporters. They had questions,' she said. 'They also wanted to share their own perspective on the experience and what they were feeling. So, we all allowed for that.' More LAUSD students stayed home this summer than usual, Patin said. And many were happy to meet up with their peers after months of being apart. Twelfth grader Andry Estrada was among them, happy to leave home at 6:30 a.m. and greet his classmates as a member of the marching band and as the secretary of the school's Associated Student Body. He said he was excited to be reunited with his classmates, some of whom had stayed home toward the end of the 2024-25 academic year for fear of immigration enforcement. 'I was definitely excited to see my teachers again and build new relationships and friendships that I haven't been able to reach in the summertime,' Estrada said. 'It's overall been a great day.' This story was originally published by EdSource. Sign up for their daily newsletter.' Solve the daily Crossword
Yahoo
4 minutes ago
- Yahoo
Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers
INDs Transferred from Statera Biopharma Advance Entolimod for ARS Along Regulatory Pathway and Enable Pursuit of Clinical Trial Program in Neutropenia and Lymphocyte Exhaustion FREMONT, Calif., August 20, 2025--(BUSINESS WIRE)--Tivic Health® Systems, Inc. (Nasdaq: TIVC), a diversified immunotherapeutics company, today announced it has received, from Statera Biopharma, two investigational new drug applications (INDs) for its lead candidate, Entolimod™. The two INDs cover the use of Entolimod to treat acute radiation syndrome, including both hematopoietic (ARS-H) and gastrointestinal (ARS-GI) sub-syndromes, and the use of Entolimod to treat advanced cancers, including as an anti-tumor agent and for conditions resulting from cancer treatments. "Transfer of these INDs to Tivic allows us to formally engage the FDA regarding Entolimod's regulatory pathway and enables clinical trials in neutropenia, lymphocyte exhaustion, and other cancer-related conditions," stated Tivic CEO, Jennifer Ernst. "While the IND for advanced cancers allows exploration of Entolimod's anti-tumor activity, building on prior developments, we remain focused in the near-term on Entolimod's first indication--acute radiation syndrome." About Entolimod Entolimod is a novel TLR5 agonist that triggers NF-kB signaling, activating antiapoptotic and cell protective mechanisms. Under the FDA's Animal Rule, Entolimod has been the subject of extensive trials for the treatment of acute radiation syndrome (ARS), and has demonstrated robust survival, enhanced GI tract recovery and improved hematopoiesis in animal models. Entolimod has been granted Fast Track Designation for ARS. Tivic also holds the exclusive rights for Entolimod for the treatment of neutropenia and has the option to license additional indications, including lymphocyte exhaustion, immunosenescence, and chronic radiation syndrome. About Tivic Tivic's dual platform strategy utilizes the body's biopharmaceutical and bioelectronic systems to treat unmet medical needs through targeting the immune system. Tivic's biologics compounds activate an innate immune pathway to prevent cell death in the bone marrow and epithelial tissues across systems impacted by radiation and age. The company's lead drug candidate, Entolimod™ for acute radiation syndrome, is a novel TLR5 agonist that has been granted Fast Track designation and is in late-stage development. Tivic's bioelectronic program is developing a novel, non-invasive medical device designed to target the neural pathways implicated in many prevalent and debilitating diseases. Early trials show promising signals that Tivic's approach may regulate specific biologic responses, and the company believes its early-stage vagus nerve stimulation device has the potential to deliver clinical outcomes similar to or better than those of surgically implanted devices. To learn more about Tivic, visit: Forward-Looking Statements This press release may contain "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will" "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems Inc.'s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of interactions with and guidance from the FDA and other regulatory authorities; changes to the company's relationship with the its partners; timing and success of clinical trials and study results; the failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company's future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company's business strategy; regulatory requirements and pathways for approval; the company's need for, and ability to secure when needed, additional working capital; the company's ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health's filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading "Risk Factors," as well as the company's subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law. View source version on Contacts Investor Contact: Hanover International, Media Contact: Deanne Eagle or Laura Min Jacksonmedia@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Yahoo
4 minutes ago
- Yahoo
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025Time: 1:00 PM - 1:30 pm, Eastern TimeLocation: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact:Donald DwyerChief Business Officerinfo@ 506-8462 Investor Relations Contact:Jami TaylorInvestor Relations Advisorinvestors@ 506-8462 Media Contact:Mark CorbaeICR 682-8288
